China’s CDE Announces “Care Plan” to Include Pfizer’s Marstaximab for Rare Disease Drug Development
The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has...
The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has...
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...
China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...